U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H31NO.ClH
Molecular Weight 337.927
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIHEXYPHENIDYL HYDROCHLORIDE

SMILES

Cl.OC(CCN1CCCCC1)(C2CCCCC2)C3=CC=CC=C3

InChI

InChIKey=QDWJJTJNXAKQKD-UHFFFAOYSA-N
InChI=1S/C20H31NO.ClH/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21;/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2;1H

HIDE SMILES / InChI
Molecular Formula C20H31NO
Molecular Weight 301.4662
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/006773_s036_artane.pdf

Trihexyphenidyl (Artane, Apo-Trihex, Parkin, Pacitane), also known as benzhexol and trihex has been in clinical usage for decades.It is an anticholinergic used in the symptomatic treatment of all etiologic groups of parkinsonism and drug induced extrapyramidal reactions (except tardive dyskinesia). Trihexyphenidyl possesses both anticholinergic and antihistaminic effects, although only the former has been established as therapeutically significant in the management of parkinsonism. Trihexyphenidyl is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Trihexyphenidyl partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinson's disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement. Trihexyphenidyl is indicated for the treatment of parkinson's disease and extrapyramidal reactions caused by drugs.

CNS Activity

Originator

Approval Year

1949
71
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 1.3 nM [IC50]
Antagonist
2849
 6.7 nM [IC50]
Antagonist
2849
 10.3 nM [IC50]
Antagonist
2849
 26.3 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Trihexyphenidyl hydrochloride

Approved Use

Trihexyphenidyl HCl tablets are indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones.

Launch Date

1949
Secondary
Approved
8583
Trihexyphenidyl hydrochloride

Approved Use

Trihexyphenidyl HCl tablets are indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones.

Launch Date

1949
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
24.4 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3225767/
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRIHEXYPHENIDYL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14.9 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3225767/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIHEXYPHENIDYL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
334 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3225767/
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRIHEXYPHENIDYL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
294 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3225767/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIHEXYPHENIDYL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.67 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3225767/
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRIHEXYPHENIDYL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3225767/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIHEXYPHENIDYL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.55 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.55 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.55 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
unhealthy, 1-18 years
Health Status: unhealthy
Age Group: 1-18 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
Disc. AE: Constipation, Gastrointestinal disorders...
AEs leading to
discontinuation/dose reduction:
Constipation (2 patients)
Gastrointestinal disorders (4 patients)
Behaviour disorder (2 patients)
Movements involuntary (1 patient)
Drowsiness (1 patient)
Skin rash (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
40 mg multiple, oral
Higher than recommended
Dose: 40 mg
Route: oral
Route: multiple
Dose: 40 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6741602/
unhealthy, 25 years
Health Status: unhealthy
Age Group: 25 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/6741602/
Other AEs: Dependence...
Other AEs:
Dependence (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6741602/
5 mg 28 times / day multiple, oral
Higher than recommended
Dose: 5 mg, 28 times / day
Route: oral
Route: multiple
Dose: 5 mg, 28 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6741602/
unhealthy, 35 years
Health Status: unhealthy
Age Group: 35 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6741602/
Other AEs: Dependence...
Other AEs:
Dependence (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6741602/
0.75 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.75 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.75 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17690057/
unhealthy, 4-15 years
Health Status: unhealthy
Age Group: 4-15 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17690057/
Disc. AE: Chorea, Rash...
AEs leading to
discontinuation/dose reduction:
Chorea (1 patient)
Rash (1 patient)
Hyperactivity (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17690057/
24 mg 1 times / day multiple, oral
Highest studied dose
Dose: 24 mg, 1 times / day
Route: oral
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6136938/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
https://pubmed.ncbi.nlm.nih.gov/6136938/
Sources:
https://pubmed.ncbi.nlm.nih.gov/6136938/
41 mg 1 times / day multiple, oral
Highest studied dose
Dose: 41 mg, 1 times / day
Route: oral
Route: multiple
Dose: 41 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6136938/
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://pubmed.ncbi.nlm.nih.gov/6136938/
Sources:
https://pubmed.ncbi.nlm.nih.gov/6136938/
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3984771/
unhealthy, mean 49.7 years
Health Status: unhealthy
Age Group: mean 49.7 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3984771/
Other AEs: Extrapyramidal symptoms...
Other AEs:
Extrapyramidal symptoms (77%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3984771/
AEs

AEs

AESignificanceDosePopulation
Drowsiness 1 patient
Disc. AE
0.55 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.55 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.55 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
unhealthy, 1-18 years
Health Status: unhealthy
Age Group: 1-18 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
Movements involuntary 1 patient
Disc. AE
0.55 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.55 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.55 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
unhealthy, 1-18 years
Health Status: unhealthy
Age Group: 1-18 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
Skin rash 1 patient
Disc. AE
0.55 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.55 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.55 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
unhealthy, 1-18 years
Health Status: unhealthy
Age Group: 1-18 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
Behaviour disorder 2 patients
Disc. AE
0.55 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.55 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.55 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
unhealthy, 1-18 years
Health Status: unhealthy
Age Group: 1-18 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
Constipation 2 patients
Disc. AE
0.55 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.55 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.55 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
unhealthy, 1-18 years
Health Status: unhealthy
Age Group: 1-18 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
Gastrointestinal disorders 4 patients
Disc. AE
0.55 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.55 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.55 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
unhealthy, 1-18 years
Health Status: unhealthy
Age Group: 1-18 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21310336/
Dependence 1 patient
40 mg multiple, oral
Higher than recommended
Dose: 40 mg
Route: oral
Route: multiple
Dose: 40 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6741602/
unhealthy, 25 years
Health Status: unhealthy
Age Group: 25 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/6741602/
Dependence 1 patient
5 mg 28 times / day multiple, oral
Higher than recommended
Dose: 5 mg, 28 times / day
Route: oral
Route: multiple
Dose: 5 mg, 28 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6741602/
unhealthy, 35 years
Health Status: unhealthy
Age Group: 35 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6741602/
Chorea 1 patient
Disc. AE
0.75 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.75 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.75 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17690057/
unhealthy, 4-15 years
Health Status: unhealthy
Age Group: 4-15 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17690057/
Hyperactivity 1 patient
Disc. AE
0.75 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.75 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.75 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17690057/
unhealthy, 4-15 years
Health Status: unhealthy
Age Group: 4-15 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17690057/
Rash 1 patient
Disc. AE
0.75 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.75 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.75 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17690057/
unhealthy, 4-15 years
Health Status: unhealthy
Age Group: 4-15 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17690057/
Extrapyramidal symptoms 77%
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3984771/
unhealthy, mean 49.7 years
Health Status: unhealthy
Age Group: mean 49.7 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3984771/
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY523868
https://www.001chemical.com/chem/144-11-6
3B Scientific (Wuhan) Corp
3B3-065679
http://www.3bsc.com/index/pro_info.php?id=104940
Aurora Fine Chemicals LLC
A12.862.769
http://online.aurorafinechemicals.com/info?ID=A12.862.769
Aurum Pharmatech LLC
H2264
http://www.Aurumpharmatech.com/Product/ProductDetails/H2264
BLD Pharm
BD41291
http://www.bldpharm.com/products/144-11-6.html
ChemMol
49416053
http://www.chemmol.com/chemmol/49416053.html
Chemspace
CSSS00020675549
https://chem-space.com/CSSS00020675549
eNovation Chemicals
D674824
https://www.enovationchem.com/ProductDetails.asp?ProductID=D674824
Hairui
HR141293
http://www.hairuichem.com/en/product/144-11-6.html
mcule
MCULE-6065307656
https://mcule.com/MCULE-6065307656/
Molcore
MC523868
https://www.molcore.com/product/144-11-6
MolPort
MolPort-001-783-510
https://www.molport.com/shop/molecule-link/MolPort-001-783-510
OChem
12132
http://www.ocheminc.com/index.php?act=psearch&pid=144T116
Parchem
30212
http://www.parchem.com/chemical-supplier-distributor/Trihexyphenidyl-020212.aspx
Smolecule
S520860
http://www.smolecule.com/products/s520860
THE BioTek
bt-261968
https://www.thebiotek.com/product/inhibitors/bt-261968
Vitas-M Laboratory
BBL024959
http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL024959&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
PubMed

PubMed

TitleDatePubMed
Anti-nicotinic properties of anticholinergic antiparkinson drugs.
1998-11
Risperidone-induced rabbit syndrome.
1998-09
Electromyography in cervical dystonia: changes after botulinum and trihexyphenidyl.
1998-09
Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism.
1998-05
Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion.
1998-01
Trihexyphenidyl withdrawal encephalopathy.
1997-01
Anticholinergic overdose induced torsade de pointes successfully treated with verapamil.
1996-11
Trihexyphenidyl as a possible therapeutic option in clozapine-induced nocturnal enuresis.
1996-03
Positron emission tomography of reversible intellectual impairment induced by long-term anticholinergic therapy.
1995-09
[A 75-year-old man with parkinsonism and delirium].
1994-01
Memory and cognitive impairments in a case of long-term trihexyphenidyl abuse.
1993-03
Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome. A case report.
1988-06
[Parkinson's disease associated with trihexyphenidyl (THP) induced dysphonia plicae ventricularis].
1988-04
Dystonic reactions with metoclopramide: is there a risk population?
1987-06
Parkinson's disease and myasthenia gravis: adverse effect of trihexyphenidyl on neuromuscular transmission.
1987-05
Lithium-induced akathisia.
1987-02
Anticholinergic-induced chorea in the treatment of focal dystonia.
1987
Bradycardia due to trihexyphenidyl hydrochloride.
1986-10
[Trihexyphenidyl (THP)-induced respiratory dyskinesia].
1986-02
Pharmacological modification of DDT-induced tremor and hyperthermia in rats: distributional factors.
1986
Withdrawal of trihexyphenidyl.
1985-03
Trihexyphenidyl dependence.
1984-06
Intravenous lorazepam in neuroleptic-induced catatonia.
1983-12
Malignant neuroleptic syndrome due to haloperidol. (A case report).
1983-01
Sexual dysfunction in women using major tranquilizers.
1982-09
Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.
1982
Akathisia: an overlooked, distressing, but treatable condition.
1981-09
Reversibility of long-term tardive dyskinesia associated with antiparkinsonian medication: a case report.
1981-08
Neuroleptic malignant syndrome.
1980-07
Extrapyramidal syndrome with sodium valproate.
1979-10-27
Choreiform movements induced by anticholinergic therapy.
1979-05-19
Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule.
1978-10-07
Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication.
1977-05
Anticholinergic exacerbation of phenothiazine-induced extrapyramidal syndrome.
1976-09
Amodiaquine-induced involuntary movements.
1976-07-24
Skeletal muscle necrosis following membrane-active drugs plus serotonin.
1976-05
[Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
1975-07-01
Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.
1974-04
Abnormal involuntary movements induced by anticholinergic therapy.
1974
Toxic liver injuries.
1973-08
Neuroleptics and neurologic reactions.
1973-03
Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study.
1973-01
An unusual response to chlorpromazine therapy.
1972-10
Benzhexol-induced blindness in Parkinson's disease.
1972-03-04
Benzhexol and side effects with long-acting fluphenazine therapy.
1972-01-29
Benzhexol-induced hallucinosis.
1971-03-06
Toxic psychosis induced by benzhexol hydrochloride.
1970-10-10
Reversal of central anticholinergic syndrome in man by physostigmine.
1968-11-25
Phenothiazines in early labour.
1967-02-11
Drug-induced extrapyramidal symptoms: their incidence and treatment.
1967-01
Patents

Patents

CN102030723B
2
US2016068510
2
US2016068514
2

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Extrapyramidal Reaction 4 to 10 mg orally each day. The total daily dose is best tolerated when administered in 2 or three equally separated doses. Usual Adult Dose for Parkinson's Disease Initial: 1 mg/day; increase by 2 mg increments at intervals of 3 to 5 days Usual dose: 6 to 10 mg/day in 3 to 4 divided doses; doses of 12 to 15 mg/day may be required Drug-induced extrapyramidal symptoms: Initial: 1 mg/day; increase as necessary to usual range of 5 to 15 mg/day in 3 to 4 divided doses Use in combination with levodopa: Usual range: 3 to 6 mg/day in divided doses
Route of Administration: Oral
In Vitro Use Guide
Trihexyphenidyl 10, 50, and 100 umol/L depressed the maximal upstroke velocity (Vmax) and the action potential amplitude (APA) of SAP in guinea pig papillary muscles.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:22:23 GMT 2025
Edited
by admin
on Mon Mar 31 18:22:23 GMT 2025
Record UNII
AO61G82577
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIHEXYPHENIDYL HYDROCHLORIDE
EP   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
BENZHEXOL HYDROCHLORIDE
WHO-IP  
Preferred Name English
ARTANE
Brand Name English
TRIHEXYPHENIDYL HYDROCHLORIDE [ORANGE BOOK]
Common Name English
BENZHEXOL HYDROCHLORIDE [WHO-IP]
Common Name English
PARCOPANE
Common Name English
TRIHEXYPHENIDYL HCL
Common Name English
ROMPARKIN
Common Name English
1-PIPERIDINEPROPANOL, .ALPHA.-CYCLOHEXYL-.ALPHA.-PHENYL-, HYDROCHLORIDE, (±)-
Systematic Name English
TRIHEXYPHENIDYL HYDROCHLORIDE [VANDF]
Common Name English
TRIHEXYPHENIDYL HYDROCHLORIDE [JAN]
Common Name English
TREMIN
Brand Name English
TRIHEXYPHENIDYL HYDROCHLORIDE [MART.]
Common Name English
CYCLODOL
Common Name English
Trihexyphenidyl hydrochloride [WHO-DD]
Common Name English
TRIHEXYPHENIDYL HYDROCHLORIDE [USP-RS]
Common Name English
CYCLODOLUM [WHO-IP]
Common Name English
(±)-.ALPHA.-CYCLOHEXYL-.ALPHA.-PHENYL-1-PIPERIDINEPROPANOL HYDROCHLORIDE
Systematic Name English
TRIPHEDINON
Common Name English
APARKANE
Common Name English
TRIHEXYPHENIDYL HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
NSC-757357
Code English
TRIHEXYPHENIDYL HYDROCHLORIDE [WHO-IP]
Common Name English
TRIHEXYPHENIDYLI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
TRIHEXYPHENIDYL HYDROCHLORIDE [MI]
Common Name English
TRIHEXYPHENIDYL HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
SEDRINA
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C38149
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
NCI_THESAURUS C29704
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
Code System Code Type Description
ECHA (EC/EINECS)
200-142-5
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
EVMPD
SUB04961MIG
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
DAILYMED
AO61G82577
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
SMS_ID
100000092344
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
EPA CompTox
DTXSID8045802
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
PUBCHEM
66007
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
ChEMBL
CHEMBL1490
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
FDA UNII
AO61G82577
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
CAS
52-49-3
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
NCI_THESAURUS
C47771
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
TRIHEXYPHENIDYL HYDROCHLORIDE
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY Description: A white or off-white, crystalline powder; odourless or almost odourless. Solubility: Slightly soluble in water; soluble in ethanol (~750 g/l) TS and methanol R. Category: Anticholinergic; antiparkinsonism drug. Storage: Trihexyphenidyl hydrochloride should be kept in a tightly closed container. Definition: Trihexyphenidyl hydrochloride contains not less than 98.0% and not more than 101.0% of C20H31NO,HCl, calculated with reference to the dried substance.
DRUG BANK
DBSALT000448
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
RXCUI
1115
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY RxNorm
NSC
757357
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
MERCK INDEX
m11134
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY Merck Index
RS_ITEM_NUM
1687006
Created by admin on Mon Mar 31 18:22:23 GMT 2025 , Edited by admin on Mon Mar 31 18:22:23 GMT 2025
PRIMARY
Related Record Type Details
Structure of TRIHEXYPHENIDYL
PARENT -> SALT/SOLVATE
Structure of TRIHEXYPHENIDYL HYDROCHLORIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of TRIHEXYPHENIDYL HYDROCHLORIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
Structure of 3-PIPERIDINOPROPIOPHENONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-PIPERIDINOPROPIOPHENONE HYDROCHLORIDE
IMPURITY -> PARENT
Related Record Type Details
Structure of TRIHEXYPHENIDYL
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966